Table 4. Correlation between KRAS mutation/KRAS overexpression and EGFR expression in CTC.
| KRAS CTC | Total | ||||
|---|---|---|---|---|---|
| Wild type | Mutated | ||||
| EGFR CTC | Negative | Count | 7 | 1 | 8 |
| % within EGFR CTC | 87.5% | 12.5% | 100.0% | ||
| % within KRAS CTC | 28.0% | 14.3% | 25.0% | ||
| % of total | 21.9% | 3.1% | 25.0% | ||
| Positive | Count | 18 | 6 | 24 | |
| % within EGFR CTC | 75.0% | 25.0% | 100.0% | ||
| % within KRAS CTC | 72.0% | 85.7% | 75.0% | ||
| % of total | 56.2% | 18.8% | 75.0% | ||
| Total | Count | 25 | 7 | 32 | |
| % within EGFR CTC | 78.1% | 21.9% | 100.0% | ||
| % within KRAS CTC | 100.0% | 100.0% | 100.0% | ||
| % of total | 78.1% | 21.9% | 100.0% | ||
| K-RAS CTC | Total | ||||
| Negative | Positive | ||||
| EGFR CTC | Negative | Count | 3 | 5 | 8 |
| % within EGFR CTC | 37.5% | 62.5% | 100.0% | ||
| % within KRAS overexpression CTC | 16.7% | 35.7% | 25.0% | ||
| % of total | 9.4% | 15.6% | 25.0% | ||
| Positive | Count | 15 | 9 | 24 | |
| % within EGFR CTC | 62.5% | 37.5% | 100.0% | ||
| % within KRAS overexpression CTC | 83.3% | 64.3% | 75.0% | ||
| % of total | 46.9% | 28.1% | 75.0% | ||
| Total | Count | 18 | 14 | 32 | |
| % within EGFR CTC | 56.2% | 43.8% | 100.0% | ||
| % within KRAS overexpression CTC | 100.0% | 100.0% | 100.0% | ||
| % of total | 56.2% | 43.8% | 100.0% | ||